Early indications show Klaviyo opening up to 20% above the IPO price
Klaviyo Inc. (KVYO) looks set to continue the trend of upbeat Wall Street debuts, as the profitable digital marketing software-as-a-service company's stock is indicated to open up to 20% above the initial public offering price. The company said late Tuesday that its IPO of 19.2 million shares priced at $30 a share, above the expected range. The stock was expected to start trading on the New York Stock Exchange some time around midday Wednesday. An early indication from the NYSE suggests the stock will open between $34 and $36, or 13.3% to 20.0% above the IPO price. At the top of that range, the company would be valued at roughly $9.1 billion. On Tuesday, shares of grocery-delivery app Instacart (CART), known officially as Maplebear Inc., opened 40% above its IPO price, before paring gains to close the day 12.3% above the IPO price. And last Thursday, shares of semiconductor-design company Arm Holdings PLC (ARM) opened 10% above its IPO price, then extended gains to close that day 24.7% above the IPO price.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-20-23 1109ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks